Table 3. Concordance, Univariable and Multivariable Cox analyses of overall survival and progression-free survival in 138 patients, with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan according to a miRNAs, gender, age, performance status and KRAS and, PI3KCA mutation status. miRNAs are tested as continuous variables in interquartile ranges units.
| OS | Concordance | Univariate | Multivariate | |||||||||
| index | lower.95 | upper.95 | P-value(single test) | HR | lower.95 | upper.95 | Wald P-value(single test) | HR | lower.95 | upper.95 | Wald P-value(multiple tests) | |
| hsa-miR-345 | 0.67 | 0.63 | 0.717 | 4.02E-15 | 2.377 | 1.804 | 3.132 | 7.70E-10 | 1.754 | 1.241 | 2.479 | 1.45E-03 |
| hsa-mir-143 | 0.63 | 0.575 | 0.683 | 2.83E-06 | 1.989 | 1.474 | 2.685 | 6.95E-06 | 1.127 | 0.777 | 1.635 | 5.28E-01 |
| hsa-miR-34a* | 0.61 | 0.555 | 0.66 | 6.76E-05 | 1.787 | 1.349 | 2.369 | 5.27E-05 | 1.191 | 0.843 | 1.683 | 3.23E-01 |
| hsa-miR-628-5p | 0.64 | 0.587 | 0.685 | 6.12E-08 | 1.693 | 1.307 | 2.195 | 6.84E-05 | 1.049 | 0.779 | 1.412 | 7.54E-01 |
| hsa-miR-886-3p | 0.6 | 0.551 | 0.658 | 1.39E-04 | 1.582 | 1.255 | 1.993 | 1.01E-04 | 1.251 | 0.923 | 1.694 | 1.49E-01 |
| hsa-miR-324-3p | 0.37 | 0.324 | 0.419 | 1.15E-07 | 0.55 | 0.428 | 0.71 | 4.17E-06 | 0.7 | 0.509 | 0.969 | 3.16E-02 |
| Gender(female vs. male) | 0.52 | 0.421 | 0.618 | 6.93E-01 | 1.088 | 0.766 | 1.545 | 6.37E-01 | 1.034 | 0.688 | 1.555 | 8.71E-01 |
| Age median(>63 vs. <63) | 0.58 | 0.482 | 0.671 | 1.14E-01 | 1.269 | 0.899 | 1.791 | 1.75E-01 | 1.301 | 0.876 | 1.931 | 1.93E-01 |
| KRAS(mt. vs. wt) | 0.6 | 0.505 | 0.7 | 3.93E-02 | 1.356 | 0.936 | 1.965 | 1.08E-01 | 1.666 | 1.109 | 2.501 | 1.39E-02 |
| PI3KCA(mt. vs. wt) | 0.49 | 0.35 | 0.637 | 9.29E-01 | 0.89 | 0.543 | 1.459 | 6.44E-01 | 0.7 | 0.414 | 1.17 | 1.71E-01 |
| Performance status(2 vs. 1 vs. 0) | 0.67 | 0.601 | 0.743 | 2.04E-06 | 1.637 | 1.288 | 2.081 | 5.57E-05 | 1.406 | 1.042 | 1.897 | 2.59E-02 |
| PFS | Concordance | Univariate | Multivariate | |||||||||
| index | lower.95 | upper.95 | P -value (single test) | HR | lower.95 | upper.95 | Wald P -value (single test) | HR | lower.95 | upper.95 | Wald P -value (multiple tests) | |
| hsa-miR-345 | 0.6 | 0.545 | 0.656 | 4.22E-04 | 1.7 | 1.313 | 2.2 | 5.53E-05 | 1.625 | 1.25 | 2.114 | 2.92E-04 |
| Gender(Female vs. Male) | 0.5 | 0.402 | 0.602 | 9.65E-01 | 0.94 | 0.661 | 1.325 | 7.08E-01 | 0.93 | 0.626 | 1.387 | 7.28E-01 |
| age.median(>63 vs. <63) | 0.58 | 0.487 | 0.675 | 9.28E-02 | 1.384 | 0.984 | 1.946 | 6.18E-02 | 1.402 | 0.953 | 2.063 | 8.65E-02 |
| KRAS(mt. vs. wt) | 0.59 | 0.492 | 0.681 | 7.31E-02 | 1.598 | 1.099 | 2.324 | 1.42E-02 | 1.633 | 1.11 | 2.401 | 1.28E-02 |
| PI3KCA(mt. vs. wt) | 0.47 | 0.331 | 0.612 | 6.91E-01 | 0.9 | 0.549 | 1.467 | 6.65E-01 | 0.79 | 0.477 | 1.293 | 3.43E-01 |
| Performance status(2 vs. 1 vs. 0) | 0.6 | 0.527 | 0.681 | 7.96E-03 | 1.318 | 1.05 | 1.653 | 1.72E-02 | 1.334 | 1.033 | 1.722 | 2.72E-02 |